Skip to main content
Erschienen in:

01.08.2008 | Editorial

Use of Erythropoietin for Cardiovascular Protection

verfasst von: Ferdinand H. Bahlmann

Erschienen in: Cardiovascular Drugs and Therapy | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Excerpt

Atherosclerotic vascular disease is a major cause of morbidity and mortality, and endothelial injury and dysfunction have been identified as crucial steps in the initiation and progression of this condition. Traditionally, it was thought that damaged and detached mature endothelial cells from the arterial wall are replaced by neighbouring cells which spread into the injured endothelial area. However, the idea that postnatal neovascularization results exclusively from remodelling through completely differentiated endothelial cells has been revised by recent findings showing that endothelial progenitor cells (EPCs) from several sources may contribute to vascular repair [13]. It is likely that these processes are of importance in the long-term evolution of vascular adaptation of patients with ischemic diseases. Thus, EPCs could be an ideal tool for vascular and hence also for organ regeneration, since experimental data demonstrated that infusion or injection of stem/progenitor cells improves heart function after myocardial infarction, or enhances blood flow in models of peripheral ischemia [4, 5]. …
Literatur
1.
Zurück zum Zitat Xu Q. The impact of progenitor cells in atherosclerosis. Nat Clin Pract Cardiovasc Med 2006;3:94–101.PubMedCrossRef Xu Q. The impact of progenitor cells in atherosclerosis. Nat Clin Pract Cardiovasc Med 2006;3:94–101.PubMedCrossRef
2.
Zurück zum Zitat Metharom P, Caplice NM. Vascular disease: a new progenitor biology. Curr Vasc Pharmacol 2007;5:61–8.PubMedCrossRef Metharom P, Caplice NM. Vascular disease: a new progenitor biology. Curr Vasc Pharmacol 2007;5:61–8.PubMedCrossRef
3.
Zurück zum Zitat Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999;18:3964–72.PubMedCrossRef Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999;18:3964–72.PubMedCrossRef
4.
Zurück zum Zitat Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006;355:1210–21.PubMedCrossRef Schachinger V, Erbs S, Elsasser A, Haberbosch W, Hambrecht R, Holschermann H, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006;355:1210–21.PubMedCrossRef
5.
Zurück zum Zitat Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004;364:141–8.PubMedCrossRef Wollert KC, Meyer GP, Lotz J, Ringes-Lichtenberg S, Lippolt P, Breidenbach C, et al. Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004;364:141–8.PubMedCrossRef
6.
Zurück zum Zitat Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007;116:85–97.PubMedCrossRef Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007;116:85–97.PubMedCrossRef
7.
Zurück zum Zitat Bahlmann FH, Song R, Boehm SM, Mengel M, von WR, Lindschau C, et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004;110:1006–12.PubMedCrossRef Bahlmann FH, Song R, Boehm SM, Mengel M, von WR, Lindschau C, et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004;110:1006–12.PubMedCrossRef
8.
Zurück zum Zitat Bahlmann FH, Kielstein JT, Haller H, Fliser D. Erythropoietin and progression of CKD. Kidney Int Suppl 2007;107:S21–S25.PubMedCrossRef Bahlmann FH, Kielstein JT, Haller H, Fliser D. Erythropoietin and progression of CKD. Kidney Int Suppl 2007;107:S21–S25.PubMedCrossRef
9.
Zurück zum Zitat Beleslin-Cokic BB, Cokic VP, Yu X, Weksler BB, Schechter AN, Noguchi CT. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 2004;104:2073–80.PubMedCrossRef Beleslin-Cokic BB, Cokic VP, Yu X, Weksler BB, Schechter AN, Noguchi CT. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 2004;104:2073–80.PubMedCrossRef
10.
Zurück zum Zitat Chatterjee PK. Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review. Naunyn Schmiedebergs Arch Pharmacol 2007;376:1–43.PubMedCrossRef Chatterjee PK. Novel pharmacological approaches to the treatment of renal ischemia-reperfusion injury: a comprehensive review. Naunyn Schmiedebergs Arch Pharmacol 2007;376:1–43.PubMedCrossRef
11.
Zurück zum Zitat Juul S. Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr Suppl 2002;91:36–42.PubMedCrossRef Juul S. Erythropoietin in the central nervous system, and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr Suppl 2002;91:36–42.PubMedCrossRef
12.
Zurück zum Zitat Lipsic E, van der Meer P, Voors AA, Westenbrink BD, van den Heuvel AF, de Boer HC, et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 2006;20:135–41.PubMedCrossRef Lipsic E, van der Meer P, Voors AA, Westenbrink BD, van den Heuvel AF, de Boer HC, et al. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 2006;20:135–41.PubMedCrossRef
13.
Zurück zum Zitat Lipsic E, Westenbrink BD, van der MP, van der HP, Voors AA, van Veldhuisen DJ, et al. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. Eur J Heart Fail 2008;10:22–9.PubMedCrossRef Lipsic E, Westenbrink BD, van der MP, van der HP, Voors AA, van Veldhuisen DJ, et al. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. Eur J Heart Fail 2008;10:22–9.PubMedCrossRef
14.
Zurück zum Zitat Cai Z, Manalo DJ, Wei G, Rodriguez ER, Fox-Talbot K, Lu H, et al. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 2003;108:79–85.PubMedCrossRef Cai Z, Manalo DJ, Wei G, Rodriguez ER, Fox-Talbot K, Lu H, et al. Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 2003;108:79–85.PubMedCrossRef
15.
Zurück zum Zitat Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003;112:999–1007.PubMed Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003;112:999–1007.PubMed
16.
Zurück zum Zitat van der Meer P, Lipsic E, Henning RH, Boddeus K, vander Velven J, Voors AA, et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005;46:125–33.PubMedCrossRef van der Meer P, Lipsic E, Henning RH, Boddeus K, vander Velven J, Voors AA, et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005;46:125–33.PubMedCrossRef
17.
Zurück zum Zitat Fliser D, Bahlmann FH, de Groot K, Haller H. Mechanisms of disease: erythropoietin—an old hormone with a new mission? Nat Clin Pract Cardiovasc Med 2006;3:563–72.PubMedCrossRef Fliser D, Bahlmann FH, de Groot K, Haller H. Mechanisms of disease: erythropoietin—an old hormone with a new mission? Nat Clin Pract Cardiovasc Med 2006;3:563–72.PubMedCrossRef
18.
Zurück zum Zitat Moon C, Krawczyk M, Paik D, Coleman T, Brines M, Juhaszova M, et al. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J Pharmacol Exp Ther 2006;316:999–1005.PubMedCrossRef Moon C, Krawczyk M, Paik D, Coleman T, Brines M, Juhaszova M, et al. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J Pharmacol Exp Ther 2006;316:999–1005.PubMedCrossRef
19.
Zurück zum Zitat Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A 1998;95:4635–40.PubMedCrossRef Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, et al. In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci U S A 1998;95:4635–40.PubMedCrossRef
20.
Zurück zum Zitat Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell’Era P, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999;93:2627–36.PubMed Ribatti D, Presta M, Vacca A, Ria R, Giuliani R, Dell’Era P, et al. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999;93:2627–36.PubMed
21.
Zurück zum Zitat Bahlmann FH, de Groot K, Spandau JM, Landry AL, Hertel B, Duckert T, et al. Erythropoietin regulates endothelial progenitor cells. Blood 2004;103:921–6.PubMedCrossRef Bahlmann FH, de Groot K, Spandau JM, Landry AL, Hertel B, Duckert T, et al. Erythropoietin regulates endothelial progenitor cells. Blood 2004;103:921–6.PubMedCrossRef
22.
Zurück zum Zitat Westenbrink BD, Oeseburg H, Kleijn L, van der HP, Belonje AM, Voors AA, et al. Erythropoietin Stimulates Normal Endothelial Progenitor Cell-Mediated Endothelial Turnover, but Attributes to Neovascularization Only in the Presence of Local Ischemia. Cardiovasc Drugs Ther 2008 DOI 10.1007/s10557-008-6094-y Westenbrink BD, Oeseburg H, Kleijn L, van der HP, Belonje AM, Voors AA, et al. Erythropoietin Stimulates Normal Endothelial Progenitor Cell-Mediated Endothelial Turnover, but Attributes to Neovascularization Only in the Presence of Local Ischemia. Cardiovasc Drugs Ther 2008 DOI 10.​1007/​s10557-008-6094-y
23.
Zurück zum Zitat Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 2003;9:1370–6.PubMedCrossRef Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 2003;9:1370–6.PubMedCrossRef
24.
Zurück zum Zitat Ii M, Nishimura H, Iwakura A, Wecker A, Eaton E, Asahara T, et al. Endothelial progenitor cells are rapidly recruited to myocardium and mediate protective effect of ischemic preconditioning via “imported” nitric oxide synthase activity. Circulation 2005;111:1114–20.PubMedCrossRef Ii M, Nishimura H, Iwakura A, Wecker A, Eaton E, Asahara T, et al. Endothelial progenitor cells are rapidly recruited to myocardium and mediate protective effect of ischemic preconditioning via “imported” nitric oxide synthase activity. Circulation 2005;111:1114–20.PubMedCrossRef
25.
Zurück zum Zitat Landmesser U, Engberding N, Bahlmann FH, Schaefer A, Wiencke A, Heineke A, et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 2004;110:1933–9.PubMedCrossRef Landmesser U, Engberding N, Bahlmann FH, Schaefer A, Wiencke A, Heineke A, et al. Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase. Circulation 2004;110:1933–9.PubMedCrossRef
26.
Zurück zum Zitat Sorrentino SA, Bahlmann FH, Besler C, Muller M, Schulz S, Kirchhoff N, et al. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 2007;116:163–73.PubMedCrossRef Sorrentino SA, Bahlmann FH, Besler C, Muller M, Schulz S, Kirchhoff N, et al. Oxidant stress impairs in vivo reendothelialization capacity of endothelial progenitor cells from patients with type 2 diabetes mellitus: restoration by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 2007;116:163–73.PubMedCrossRef
27.
Zurück zum Zitat Johnson DW, Pat B, Vesey DA, Guan Z, Endre Z, Gobe GC. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 2006;69:1806–13.PubMedCrossRef Johnson DW, Pat B, Vesey DA, Guan Z, Endre Z, Gobe GC. Delayed administration of darbepoetin or erythropoietin protects against ischemic acute renal injury and failure. Kidney Int 2006;69:1806–13.PubMedCrossRef
28.
Zurück zum Zitat Sharples EJ, Thiemermann C, Yaqoob MM. Mechanisms of disease: Cell death in acute renal failure and emerging evidence for a protective role of erythropoietin. Nat Clin Pract Nephrol 2005;1:87–97.PubMedCrossRef Sharples EJ, Thiemermann C, Yaqoob MM. Mechanisms of disease: Cell death in acute renal failure and emerging evidence for a protective role of erythropoietin. Nat Clin Pract Nephrol 2005;1:87–97.PubMedCrossRef
29.
Zurück zum Zitat Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003;112:999–1007.PubMed Parsa CJ, Matsumoto A, Kim J, Riel RU, Pascal LS, Walton GB, et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 2003;112:999–1007.PubMed
30.
Zurück zum Zitat Fuste B, Serradell M, Escolar G, Cases A, Mazzara R, Castillo R, et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost 2002;88:678–85.PubMed Fuste B, Serradell M, Escolar G, Cases A, Mazzara R, Castillo R, et al. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemost 2002;88:678–85.PubMed
31.
Zurück zum Zitat Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000;95:2983–9.PubMed Stohlawetz PJ, Dzirlo L, Hergovich N, Lackner E, Mensik C, Eichler HG, et al. Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans. Blood 2000;95:2983–9.PubMed
32.
Zurück zum Zitat Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071–84.PubMedCrossRef Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006;355:2071–84.PubMedCrossRef
33.
Zurück zum Zitat Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085–98.PubMedCrossRef Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006;355:2085–98.PubMedCrossRef
34.
Zurück zum Zitat Yonekura S, Chern Y, Donahue KA, Feldman L, Vanasse GJ, Sytkowski AJ. Erythropoietin receptors induced by dimethyl sulfoxide exhibit positive cooperativity associated with an amplified biologic response. Proc Natl Acad Sci U S A 1991;88:2535–9.PubMedCrossRef Yonekura S, Chern Y, Donahue KA, Feldman L, Vanasse GJ, Sytkowski AJ. Erythropoietin receptors induced by dimethyl sulfoxide exhibit positive cooperativity associated with an amplified biologic response. Proc Natl Acad Sci U S A 1991;88:2535–9.PubMedCrossRef
35.
Zurück zum Zitat Lipsic E, Westenbrink BD, van der MP, van der HP, Voors AA, van Veldhuisen DJ, et al. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. Eur J Heart Fail 2008;10:22–9.PubMedCrossRef Lipsic E, Westenbrink BD, van der MP, van der HP, Voors AA, van Veldhuisen DJ, et al. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit. Eur J Heart Fail 2008;10:22–9.PubMedCrossRef
36.
Zurück zum Zitat vander Meer P, Lipsic E, Henning RH, Boddeus K, vander Velden J, Voors AA, et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005;46:125–33.CrossRef vander Meer P, Lipsic E, Henning RH, Boddeus K, vander Velden J, Voors AA, et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005;46:125–33.CrossRef
Metadaten
Titel
Use of Erythropoietin for Cardiovascular Protection
verfasst von
Ferdinand H. Bahlmann
Publikationsdatum
01.08.2008
Verlag
Springer US
Erschienen in
Cardiovascular Drugs and Therapy / Ausgabe 4/2008
Print ISSN: 0920-3206
Elektronische ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-008-6111-1

Weitere Artikel der Ausgabe 4/2008

Cardiovascular Drugs and Therapy 4/2008 Zur Ausgabe

Neu im Fachgebiet Kardiologie

Nach dem Nitrospray fünf Minuten mit der Kardio-CT warten!

19.07.2024 Koronare Herzerkrankung Nachrichten

Nach Verabreichung von sublingualem Nitrospray vor einer CT-Koronarangiografie sollte man unbedingt die in Leitlinien empfohlene Wartezeit einhalten, rät ein kardiologisches Team aus Belgien.

Welche Antikoagulation bei Vorhofflimmern und Leberzirrhose?

19.07.2024 Leberzirrhose Nachrichten

Bei einer Auswertung von US-Versicherungsdaten ging es um die Frage, welche Antikoagulation –  Apixaban, Rivaroxaban oder Warfarin – bei Personen mit Leberzirrhose und Vorhofflimmern unterm Strich die beste Prophylaxe-Option ist.     

Mehrgefäßstenosen einzeitig oder zweizeitig eröffnen?

18.07.2024 Gefäßstenosen Nachrichten

Nach einem Herzinfarkt mit Mehrgefäßerkrankung sind bessere Ergebnisse zu erwarten, wenn alle stenotischen Abschnitte revaskularisiert werden. Sollte das in einer oder in mehreren Sitzungen geschehen? Eine Metaanalyse gibt eine klare Antwort.

Erste zielgerichtete Therapie zur Behandlung der hypertrophen obstruktiven Kardiomyopathie

18.07.2024 Kardiomyopathie Nachrichten

Mit Mavacamten von Bristol Myers Squibb ist erstmals eine zielgerichtete Therapie der hypertrophen obstruktiven Kardiomyopathie (HOCM) verfügbar. Der Myosin-Inhibitor verhindert die bei HOCM übermäßige Bildung von Aktin-Myosin-Querbrücken und verbessert die Symptomatik und die Lebensqualität von Betroffenen.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.